Conclusions
SECONDARY
In this prespecified secondary analysis of the CHANCE-2 randomized clinical trial, we found no treatment-by-metabolizer status interaction. The relative clinical efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin were similar across 